Opportunities
Search

Buyer: Viešoji įstaiga CPO LT | Notice type: cn-standard | Procedure: restricted | Contract: supplies | Deadline: 2026-10-02

Buyer: Viešoji įstaiga CPO LT | Notice type: cn-standard | Procedure: restricted | Contract: supplies | Deadline: 2026-10-02

The National Institute on Deafness and Other Communication Disorders (NIDCD) invites applications for Clinical Research Center Grants designed to advance the diagnosis, prevention, treatment, and amelioration of human sensory and communication disorders. For this announcement, Clinical Research is defined as research involving individuals with a sensory and/or communication disorder, or data/tissues from individuals with a sensory and/or communication disorder. Examples of such research include but are not limited to, studies of the prevention, pathogenesis, pathophysiology, diagnosis, treatment, management or epidemiology of a disease or disorder of hearing, balance, smell, taste, voice, speech, or language. Although the intent is that all the research will involve individuals with sensory and/or communication disorders or data/tissues from individuals with sensory and/or communication disorders, when the clinical research goal(s) warrant(s) limited departures from this intent, alternatives (e.g., non-human research, human subjects without a sensory or communication disorder, human at risk for a sensory and/or communication disorder) are possible with appropriate and strong scientific justification and in consultation with NIDCD staff. Applications may propose a low-risk clinical trial but are not required to (optional).Non-responsive applications will not be reviewed. Prospective applicants are strongly encouraged to read this funding opportunity carefully and communicate with the scientific/research contact listed at the end of this award as early as possible to discuss....

Buyer: European Central Bank | Notice type: cn-standard | Procedure: restricted | Contract: services | Deadline: 2026-10-03

Buyer: European Central Bank | Notice type: cn-standard | Procedure: restricted | Contract: services | Deadline: 2026-10-03

Buyer: Hlavné mesto Slovenskej republiky Bratislava | Notice type: cn-standard | Procedure: restricted | Contract: services | Deadline: 2026-10-03

Buyer: Univerzitná nemocnica Martin | Notice type: cn-standard | Procedure: restricted | Contract: supplies | Deadline: 2026-10-04

Buyer: Univerzitná nemocnica Martin | Notice type: cn-standard | Procedure: restricted | Contract: supplies | Deadline: 2026-10-04

Buyer: Univerzitná nemocnica Martin | Notice type: cn-standard | Procedure: restricted | Contract: supplies | Deadline: 2026-10-04

Summary: The fiscal year 2026 (FY26) Peer Reviewed Cancer Research Program (PRCRP) Idea Award (IA) supports innovative, untested, high-risk/potentially high-reward concepts, theories, paradigms, and/or basic cancer research. The advancement of knowledge in cancer research, patient care, and/or treatment options in the Military Health System (MHS) is critical to Service Members, Veterans, other military beneficiaries and the American public.Distinctive Features: The proposed project should demonstrate creative thinking and innovation.• Incremental advances, the next logical step, or switching a model system from one cancer to another cancer are not appropriate for this award.• Inclusion of preliminary data is not required; however, the project must be based on strong scientific rationale.• New for FY26: Early Career Investigator Option: The Early Career Investigator option is designed to support the continued development of promising independent investigators that are early in their faculty appointments.

Summary: The fiscal year 2026 (FY26) Peer Reviewed Cancer Research Program (PRCRP) Impact Award supports mature research that will have a near-term impact on clinical cancer care in one of the congressionally directed FY26 PRCRP Topic Areas. Applicants must consider how the research project will lead to the advancement of knowledge in cancer research, patient care and/or treatment options in the Military Health System (MHS).Distinctive Features:• Applications must include preliminary data to support feasibility of the study.• Projects must have strong potential to result in a near-term impact in cancer.• The funding mechanism allows clinical trials.• This funding mechanism allows for a single Principal Investigator (PI), or two partnering PIs referred to as the Initiating PI and the Partnering PI. Only the Initiating PI will submit a pre-application, but both PIs will need to submit full applications. The Partnering PI’s application is an abbreviated package specific to their distinct portion of the research project. Be advised, both applications for a research project may be withdrawn if the initiating or partnering application is rejected or administratively withdrawn.

Summary: The fiscal year 2026 (FY26) Peer Reviewed Cancer Research Program (PRCRP) Clinical Trial Award (CTA) supports the rapid implementation of clinical trials with the potential to have a significant impact on the treatment or management of cancer within at least one of the FY26 PRCRP Topic Areas. Clinical trials proposed may evaluate promising new products, pharmacologic agents (drugs or biologics), devices, clinical guidance, and/or emerging approaches and technologies. Proposed projects may range from small proof-of-concept trials (e.g., pilot, first-in-human, phase 0) that evaluate the effects of interventions or inform the design of more advanced trials to large-scale trials (up to phase III) to determine efficacy in relevant patient populations.Distinctive Features:• Applications to this award mechanism must include a clinical trial.• Projects can range from phase 0 to phase III.• If an Investigational New Drug (IND) application, Investigational Device Exemption (IDE), or equivalent, is required, a regulatory application must be submitted to the relevant regulatory agency by the Clinical Trial Award application submission deadline. The regulatory application should be specific to the product and indication to be tested in the proposed clinical trial.• Applications are required to include patient advocates.• Animal studies are NOT allowed under this award mechanism. All preclinical work must be completed prior to the award start date.

Buyer: Gemeente Nieuwegein | Notice type: cn-standard | Procedure: open | Contract: services | Deadline: 2026-10-05

Buyer: Stadswerk 072 N.V. | Notice type: cn-standard | Procedure: open | Contract: services | Deadline: 2026-10-05

Buyer: Rijkswaterstaat Programma's, Projecten en Onderhoud | Notice type: cn-standard | Procedure: open | Contract: services | Deadline: 2026-10-05

Buyer: Gemeente Lansingerland | Notice type: cn-standard | Procedure: open | Contract: supplies | Deadline: 2026-10-05

Buyer: Region Östergötland | Notice type: cn-standard | Procedure: open | Contract: supplies | Deadline: 2026-10-05

Buyer: Métropole Aix Marseille Provence | Notice type: cn-standard | Procedure: open | Contract: services | Deadline: 2026-10-05

Buyer: Vivantes - Netzwerk für Gesundheit GmbH | Notice type: cn-standard | Procedure: open | Contract: works | Deadline: 2026-10-05

Buyer: Stadswerk 072 N.V. | Notice type: cn-standard | Procedure: open | Contract: services | Deadline: 2026-10-05

Buyer: Anculus B.V. | Notice type: cn-standard | Procedure: open | Contract: supplies | Deadline: 2026-10-05

Buyer: Gemeenschappelijke Regeling Belastingsamenwerking gemeenten en hoogheemraadschap Utrecht (BghU) | Notice type: cn-standard | Procedure: open | Contract: services | Deadline: 2026-10-05

Buyer: AP-HP Sorbonne Université | Notice type: cn-standard | Procedure: open | Contract: works | Deadline: 2026-10-05

Buyer: Gemeente Tytsjerksteradiel | Notice type: cn-standard | Procedure: open | Contract: supplies | Deadline: 2026-10-05

Buyer: Conseil départemental de la Haute-Garonne | Notice type: cn-standard | Procedure: open | Contract: works | Deadline: 2026-10-05